0000000000960110

AUTHOR

Carlos H Barrios

showing 1 related works from this author

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-…

2019

Altres ajuts: Agustí Barnadas: Honoraria: Pfizer. Consulting or Advisory Role: Pfizer, Novartis, Eli Lilly. Speakers'Bureau: Roche, Pfizer, Novartis, Genomic Health International. Travel, Accommodations, Expenses: Roche, Pfizer; Miguel A. Seguí: Consulting or Advisory Role: Roche, Pfizer, Novartis, Amgen, Eisai, Eli Lilly. Speakers' Bureau: Roche, Pfizer, Amgen. Research Funding: Roche (Inst), Novartis (Inst). Travel, Accommodations, Expenses: Roche, Pfizer, Novartis, Amgen. Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of sta…

Adult0301 basic medicineSubset AnalysisOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyAxillary lymph nodesmedicine.medical_treatmentTriple Negative Breast NeoplasmsDisease-Free SurvivalCapecitabineYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineCapecitabineNeoadjuvant therapyTriple-negative breast cancerAgedChemotherapyTaxanebusiness.industryHazard ratioMiddle AgedNeoadjuvant Therapy030104 developmental biologymedicine.anatomical_structureOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemalebusinessmedicine.drug
researchProduct